The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: Can it successfully predict outcome and guide intervention?

Pediatric Blood and Cancer

Volumn 47, Issue 2, 2006, Pages 200-205

  Greenfield, Hayley M ^a,b   Gharib, Maged I ^a   Turner, Andrew J L ^b   Guiver, Malcolm ^b   Carr, Trevor ^a   Will, Andrew M ^a   Wynn, Robert F ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Epstein Barr virus; Haemopoietic stem cell transplant; Post transplant lymphoproliterative disorder

Indexed keywords

RITUXIMAB;

ARTICLE; BONE MARROW TRANSPLANTATION; EPSTEIN BARR VIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOPROLIFERATIVE DISEASE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; VIRUS REACTIVATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; INFANT; LYMPHOPROLIFERATIVE DISORDERS; MALE; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD; VIRUS ACTIVATION;

EID: 33745793624     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20604     Document Type: Article

References (21)

1. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988;71:1234-1243.
2. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997;15:405-431.
3. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A multiinstitutional study. Blood 1999;94:2208-2216.
4. Socié G, Curtis RE, Deeg HG, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukaemia. J Clin Oncol 2000;18:348-357.
5. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusion of donor leucocytes to treat Epstein-Barr Virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-1191.
6. Rooney CM, Smith CA, Ng CY, et al. Use of gene modified virus specific T lymphocytes to control Epstein-Barr virus related lymphoproliferation. Lancet 1995;345:9-13.
7. Faye A, Quartier P, Reguerre Y, et al. Chimaeric anti-CD20 monoclonal antibody rituximab in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001;115:112-118.
8. Hoshino Y, Kimura H, Tanaka N, et al. Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogeneic stem cell transplantation. Br J Haematol 2001;115:105-111.
9. van Esser JWJ, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001;98:972-978.
10. Gärtner BC, Schäfer H, Marggraff K, et al. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor post transplant lymphoproliferative disease. J Clin Microbiol 2002;40:351-358.
11. Hale G, Waldmann H. Risks of developing Epstein-Barr virus related lymphoproliferative disorders after T-cell depleted marrow transplants. Blood 1998;91:3079-3083.
12. Cavazzano-Calvo M, Bensoussan D, Jabado N, et al. Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depletedbone marrow transplantation. Br J Haematol 1998;103:543-551.
13. Wagner H, Cheng YC, Huls H, et al. Prompt versus pre-emptive intervention for EBV lymphoproliferative disease. Blood 2004;103:3979-3981.
14. Lucas KG, Small TN, Heller G, et al. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996;87:2594-2603.
15. Rooney CM, Smith CA, Ng CYC, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-1555.
16. Small TN, Papadopoulos EB, Boulad F, et al. Comparison of immune reconstitution after unrelated and related T-cell depleted bone marrow transplantation: Effect of patient age and donor leukocyte infusions. Blood 1999;93:467-480.
17. Marshall NA, Howe JG, Formica R, et al. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood 2000;96:2814-2821.
18. Clave E, Agbalika F, Bajzik V, et al. Epstein-Barr virus (EBV) reactivation in allogeneic stem cell transplantation: Relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation 2004;77:76-84.
19. van Esser JWJ, Niesters HGM, van der Holt B, et al. Prevention of Epstein-Barr virus lymphoproliferative disease by molecular monitoring and pre-emptive rituximab in high risk patients after allogeneic stem cell transplantation. Blood 2002;99:4364-4369.
20. van Esser JWJ, Niesters, HGM, Thijsen SFT, et al. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol 2001;113:814-821.
21. Koehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after haemopoietic stem cell transplantation. Blood 2000;95:1502-1505.